• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.

作者信息

Kaneda Hiroyasu, Okamoto Isamu, Nakagawa Kazuhiko

机构信息

Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan.

出版信息

J Thorac Oncol. 2013 Apr;8(4):e32-3. doi: 10.1097/JTO.0b013e3182843771.

DOI:10.1097/JTO.0b013e3182843771
PMID:23486271
Abstract
摘要

相似文献

1
Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.间变性淋巴瘤激酶（ALK）重排阳性非小细胞肺癌患者脑转移对克唑替尼的快速反应
J Thorac Oncol. 2013 Apr;8(4):e32-3. doi: 10.1097/JTO.0b013e3182843771.
2
Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.克唑替尼治疗ALK重排转移性非小细胞肺癌脑转移的有效给药方案。
J Thorac Oncol. 2013 Dec;8(12):e112-3. doi: 10.1097/JTO.0000000000000038.
3
Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.一名14岁ALK阳性非小细胞肺癌女孩对克唑替尼有显著的肿瘤反应。
J Clin Oncol. 2012 Jun 1;30(16):e147-50. doi: 10.1200/JCO.2011.39.9766. Epub 2012 Apr 16.
4
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.ALK基因中I1171位点的二次突变赋予了对克唑替尼和阿来替尼的耐药性。
J Thorac Oncol. 2014 Dec;9(12):e86-7. doi: 10.1097/JTO.0000000000000358.
5
Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.克唑替尼对两例伴有EML4-ALK重排的肺腺癌脑转移无效。
J Thorac Oncol. 2013 Apr;8(4):e30-1. doi: 10.1097/JTO.0b013e318288dc2d.
6
Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.在不存在ALK突变的情况下对ALK抑制剂克唑替尼产生获得性耐药。
J Thorac Oncol. 2012 Mar;7(3):623-5. doi: 10.1097/JTO.0b013e318241daab.
7
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.一名免疫组化阳性、荧光原位杂交阴性的间变性淋巴瘤激酶（ALK）非小细胞肺癌患者对克唑替尼产生显著反应。
J Thorac Oncol. 2012 Dec;7(12):e36-e38. doi: 10.1097/JTO.0b013e318274694e.
8
ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?对克唑替尼有反应的ALK重排鳞状细胞肺癌：非小细胞肺癌领域中缺失的环节？
Lung Cancer. 2016 Jan;91:67-9. doi: 10.1016/j.lungcan.2015.11.010. Epub 2015 Nov 10.
9
Treatment and detection of ALK-rearranged NSCLC.ALK 重排非小细胞肺癌的治疗与检测。
Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12.
10
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.克唑替尼治疗晚期ALK重排非小细胞肺癌合并脑转移患者的临床经验
J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26.

引用本文的文献

1
Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer.非小细胞肺癌患者中c-Myc、ALK、ROS1、BRAF和PD-L1的表达及预后意义
Clin Med Insights Oncol. 2022 Apr 22;16:11795549221092747. doi: 10.1177/11795549221092747. eCollection 2022.
2
Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors.间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌患者的最佳治疗：ALK抑制剂的作用和应用综述
Cancer Manag Res. 2020 Jul 30;12:6615-6628. doi: 10.2147/CMAR.S260274. eCollection 2020.
3
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
克唑替尼与铂类化疗作为不同 ROS1 融合变异晚期非小细胞肺癌的一线治疗。
Cancer Med. 2020 May;9(10):3328-3336. doi: 10.1002/cam4.2984. Epub 2020 Mar 13.
4
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.治疗间变性淋巴瘤激酶重排非小细胞肺癌脑转移
Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17.
5
Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.ALK 阳性晚期非小细胞肺癌患者克唑替尼耐药后生存的有利预测因素。
Thorac Cancer. 2019 May;10(5):1096-1102. doi: 10.1111/1759-7714.13050. Epub 2019 Mar 28.
6
Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib.聚焦布加替尼及其在治疗对克唑替尼耐药或不耐受的转移性ALK阳性非小细胞肺癌患者中的潜力。
Lung Cancer (Auckl). 2017 Oct 13;8:169-177. doi: 10.2147/LCTT.S126507. eCollection 2017.
7
Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report.克唑替尼治疗ALK阳性中枢神经系统炎性肌纤维母细胞瘤的疗效：一例报告
Cureus. 2017 Mar 2;9(3):e1068. doi: 10.7759/cureus.1068.
8
Systemic treatment of non-small cell lung cancer brain metastases.非小细胞肺癌脑转移的全身治疗
Contemp Oncol (Pozn). 2016;20(5):352-357. doi: 10.5114/wo.2016.64593. Epub 2016 Dec 20.
9
First-line treatment of advanced ALK-positive non-small-cell lung cancer.晚期ALK阳性非小细胞肺癌的一线治疗。
Lung Cancer (Auckl). 2015 Sep 18;6:71-82. doi: 10.2147/LCTT.S63491. eCollection 2015.
10
Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.非小细胞肺癌中枢神经系统转移灶中NRAS、PTEN和AKT1基因突变的发生率
Brain Tumor Pathol. 2017 Jan;34(1):36-41. doi: 10.1007/s10014-016-0276-2. Epub 2017 Jan 17.